Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Trading Down 1.7% – Should You Sell?

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR)’s stock price traded down 1.7% during trading on Monday . The stock traded as low as $23.92 and last traded at $24.02. 1,456 shares changed hands during mid-day trading, a decline of 30% from the average session volume of 2,080 shares. The stock had previously closed at $24.43.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

The company’s 50 day moving average price is $24.50 and its 200 day moving average price is $25.15. The company has a market cap of $4.08 million, a price-to-earnings ratio of 24.31 and a beta of 0.40.

Institutional Investors Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently bought a new position in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC bought a new stake in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned approximately 10.02% of Amplify Weight Loss Drug & Treatment ETF as of its most recent filing with the SEC.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.